Loading
A phase 2 trial of Olaparib and Durvalumab in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer is a phase 2 interventional study registered as NCT05498155 by AstraZeneca, with 50 participants enrolled, started 2022-11-07 and due to reach its primary completion in 2024-11-20. Interventions recorded: Neoadjuvant Olaparib monotherapy group and Neoadjuvant combination therapy with olaparib plus durvalumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP inhibitors, Olaparib, Durvalumab, AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares PARP inhibitors, Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/